Related Experiment Video
Updated: Jul 8, 2026
12:04
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
B-cell-directed therapies in systemic lupus erythematosus
1Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.
Seminars in Arthritis and Rheumatism
|January 22, 2008
Summary
Novel therapies targeting B-cells show promise for treating systemic lupus erythematosus (SLE). B-cell depletion and costimulatory pathway modulation offer potential, while anticytokine agents require further study for SLE treatment.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- B-cells play a crucial role in the pathogenesis and flares of systemic lupus erythematosus (SLE).
- Targeting B-cells has become a significant therapeutic strategy for managing SLE.
- Understanding B-cell functions is key to developing effective SLE treatments.
Purpose of the Study:
- To review existing literature on B-cell-directed therapies for SLE.
- To focus on B-cell depletion, tolerance, costimulatory signals, and cytokines impacting B-cell activity.
- To evaluate the efficacy and potential of various B-cell-targeted treatments for SLE.
Main Methods:
- Literature search of PubMed and Clinical Trials databases (2002-2007).
- Keywords: B-cells, SLE, therapy.
- Review of 17 completed and 5 ongoing clinical trials.
Main Results:
- B-cell-depleting therapies (rituximab, epratuzumab) showed positive results in SLE treatment.
- LJP 394, a B-cell tolerogen, did not demonstrate significant clinical benefit.
- Costimulatory pathway targeting yielded variable results; anti-CD40L trials were halted, while B7-CD28 pathways appear promising.
- Newer anticytokine agents (anti-BLyS, IL-10, IL-6, IFN-alpha) require further investigation for SLE.
Conclusions:
- Technological advancements have expanded the range of B-cell-directed therapies for SLE.
- Targeted treatments offer the potential for personalized therapeutic approaches in specific SLE patient subpopulations.
- Novel therapies offer an alternative to general immunosuppressants by interfering with specific B-cell functions.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:22iPS Cell Differentiation
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.